Rimonabant induces partial seizures in a patient with a history of generalized epilepsy: Letters/commentary

Epilepsia

Volumn 50, Issue 9, 2009, Pages 2171-2172

  Braakman, Hilde M H ^a   Van Oostenbrugge, Robert J ^a,b   Van Kranen Mastenbroek, V H J M ^a,b   De Krom, Marc C T F M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; RIMONABANT;

ADULT; CARDIOVASCULAR RISK; CASE REPORT; DIABETES MELLITUS; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; FALLING; FOCAL EPILEPSY; FOOD AND DRUG ADMINISTRATION; GENERALIZED EPILEPSY; HUMAN; HYPERTENSION; LETTER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PRIORITY JOURNAL; TONIC CLONIC SEIZURE;

ANTI-OBESITY AGENTS; COMORBIDITY; EATING; EPILEPSIES, PARTIAL; EPILEPSY, GENERALIZED; HUMANS; MALE; MIDDLE AGED; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID;

EID: 69149097494     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2009.02203.x     Document Type: Letter

References (6)

1. Després JP, Golay A, Sjöström L Rimonabant in Obesity-Lipids Study Group 2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 : 2121 2134.
2. Ludányi A, Eross L, Czirják S, Vajda J, Halász P, Watanabe M, Palkovits M, Maglóczky Z, Freund TF, Katona I 2008) Downregulation of the cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus. J Neurosci 28 : 2976 2990.
3. Monory K, Massa F, Egertová M, Eder M, Blaudzun H, Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, Long J, Rubenstein JL, Goebbels S, Nave KA, During M, Klugmann M, Wölfel B, Dodt HU, Zieglgänsberger W, Wotjak CT, Mackie K, Elphick MR, Marsicano G, Lutz B 2006) The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51 : 455 466.
4. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J RIO-North America Study Group 2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295 : 761 775.
5. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF RIO-Diabetes Study Group 2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368 : 1660 1672.
6. Wallace MJ, Martin BR, DeLorenzo RJ 2002) Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol 452 : 295 301.